Modified FOLFOX-6 chemotherapy in advanced gastric cancer
Author Information
Author(s): Keam Bhumsuk, Im Seock-Ah, Han Sae-Won, Ham Hye Seon, Kim Min A, Oh Do-Youn, Lee Se-Hoon, Kim Jee Hyun, Kim Dong-Wan, Kim Tae-You, Heo Dae Seog, Kim Woo Ho, Bang Yung-Jue
Primary Institution: Seoul National University Hospital
Hypothesis
The study aimed to evaluate the efficacy and toxicity of modified FOLFOX-6 chemotherapy in patients with advanced gastric cancer and analyze the predictive value of genetic polymorphisms.
Conclusion
Modified FOLFOX-6 chemotherapy appears to be active and well tolerated as first-line chemotherapy in advanced gastric cancer patients.
Supporting Evidence
- The overall response rate was 43.8%.
- Median time to progression was 6.0 months.
- Median overall survival was 12.6 months.
- Toxicities were generally tolerable and manageable.
- The 6-bp deletion in TS-3'UTR was significantly associated with prolonged TTP and OS.
- Performance status was a statistically significant prognostic factor for TTP.
Takeaway
This study tested a new chemotherapy for stomach cancer and found it works well and is safe for patients.
Methodology
Seventy-three patients received modified FOLFOX-6 chemotherapy, and genetic polymorphisms were analyzed for their predictive value.
Limitations
The study had a small sample size and was conducted at a single institution.
Participant Demographics
{"gender":{"male":48,"female":25},"age":{"median":59,"range":"24-77"},"performance_status":{"ECOG 0-1":60,"ECOG 2":13},"histopathologic_type":{"intestinal":47,"diffuse":23,"unknown":3}}
Statistical Information
P-Value
p = 0.034
Confidence Interval
{"overall_survival":"95% CI, 8.7–16.5 months","time_to_progression":"95% CI, 4.8–7.2 months"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website